Prevalence of Candidemia with Susceptibility Pattern in a Tertiary Care Hospital in North India

Ashish William¹, Aroma Oberoi², Divya Dsouza³, Arpit Oberoi⁴

¹,² Department of Microbiology, Christian Medical College & Hospital, Ludhiana, Punjab, India.
³,⁴ Christian Medical College & Hospital, Ludhiana, Punjab, India.

ABSTRACT

BACKGROUND
Bloodstream infections (BSI) caused by various candida species have been reported from many countries worldwide and are a significant cause of morbidity and mortality in hospitalised patients. The alarming increase in infections with multidrug resistant bacteria is due to overuse of broad-spectrum antimicrobials, which leads to overgrowth of candida species; thus, enhancing its opportunity to cause the disease. During recent decades, there has been a change in the epidemiology of candida infections, characterised by a progressive shift from a predominance of *Candida albicans* to non-albicans candida species. This study was conducted to determine the prevalence of candidemia in blood stream and the susceptibility pattern in a tertiary care hospital in North India.

METHODS
This is retrospective study which has been conducted for a period of 1.5 years form April 2015 to October 2016. All blood cultures received during this period by BACTEC automated culture system and Becton Dickinson were included in the study. The culture was done on positive blood culture bottles and were cultured on Sabouraud dextrose agar. Recovered candida isolates were speciated and antifungal susceptibility testing was performed as per Clinical and Laboratory Standards Institute guidelines (CLSI).

RESULTS
A total of 80 out of 8020 blood cultures were culture positive for candida species. Therefore, the overall prevalence rate of isolation of candida species was 0.99 % in our study. The incidence of blood stream infection caused by non albicans candida species (73.8 %) was higher than *Candida albicans* (26.2 %). Among NAC species, *Candida tropicalis* (44 %) was the most common, followed by *Candida parapsilosis* (24 %), *Candida glabrata* (17 %), *Candida krusei* (8.5 %), *Candida guilliermondii* (5 %) and *Candida dubliniensis* (1.5 %). Candidemia was predominantly observed in ICU patients. Resistance was significantly higher among non-albicans candida species (NAC), amphotericin B, fluconazole, ketoconazole, itraconazole and clotrimazole - 96.72 %, 59.84 %, 51.23 %, 19.44 %, and 56.15 % respectively.

CONCLUSIONS
With an ever-expanding array of non-candida species-related infections in highly compromised and terminally ill patients, understanding the activity of the antifungal agents used against both *C. albicans* and nonalbicans species becomes mandatory. Continued surveillance of candida infections will be required to document changes in epidemiology and antifungal susceptibilities.

KEYWORDS
Bloodstream Infections, Candidemia, Non Albicans Candida (NAC)
BACKGROUND

Over the last few years, the incidence of fungal infections caused by opportunistic fungal pathogens, such as yeasts and yeast-like species, has witnessed a dramatic increase. The most important yeasts isolated from clinical specimens are candida species. These species infect hospitalised patients, especially those admitted to intensive care units or oncology wards. Invasive candida infection has been associated with high mortality.1-2

The importance of candida species as a cause of BSI has been highlighted in many studies in the past few years. In the hospital set up in United States, candida species has been considered as one of most common cause of blood stream infections.3

Among patients admitted in intensive care units (ICUs), those admitted in surgical ICUs (SICUs) are considered to be at a greater risk for developing candidemia.4 There are many risk factors which can lead to the development of candidemia in surgical ICU, along with wide variation in infection rates between institutions with the highest rates of candidemia seen in urban hospitals caring for trauma patients. The risk factors independently associated with development of candidemia includes prior surgery, acute renal failure and parenteral nutrition. An elevated acute physiology and chronic health evaluation II (APACHE) score can help identify ICU patients who can have a higher risk of developing candidemia which may help in diagnosis.4 SICU patients had a longer duration of antibiotic therapy and received a larger number of antibiotics than patients admitted in MICU. SICU patients also have other risk factors like total parenteral nutrition (TPN) and central venous catheters (CVCs).5

More than 90 % of the invasive infections due to candida are attributed to five species; C. albicans, C. glabrata, C. parapsilosis, C. tropicalis and C. krusei. However, the list of new species of candida isolated from clinical specimens continues to grow every year.6

In contrast to the United States (US) scenario, in many other countries, C. tropicalis and C. parapsilosis have become the most common candida species to cause BSI.7 In India, C. tropicalis is now the most common cause of nosocomial candidemia. C. tropicalis has been seen to be covering around 67 - 90 % of cases of candidemia.7-8 The increased use of fluconazole has been determined to be the major cause of predominance of non-albicans candida, especially C. tropicalis over C. albicans.8 Among the non-albicans candida species, C. glabrata has emerged as an important opportunistic pathogen worldwide. It is the second most common yeast isolated as part of normal flora and its role as a pathogen has only been recognised in the past few decades. In today’s era, there has been a considerable increase in the isolation rate of C. glabrata from BSI in ICUs.9

Apart from resistance to antifungal agents which is one of the most important causes of antifungal treatment failure, many other factors also play important roles in this. Host factors like severity of the illness or immunosuppression can lead to treatment failure. Decreased bioavailability and decreased concentration of the drug at the target site due to various pharmacokinetic and pharmacodynamic variables also lead to antifungal treatment failure.

Antifungal prophylaxis is commonly used in patients with specific risk factors like malignancies, transplant patients and patients with neutropenia. Whereas guidelines for the treatment of candidemia are available, the role of prophylactic or empirical therapy in preventing candidemia or decreasing the mortality rate associated with it is not very clear.

Empirical therapy is instituted before the diagnosis of candidemia. Because of the high mortality associated with delayed therapy in candidemia especially in neutropenic patients, empirical therapy with anti-fungal drugs is usually advocated for such patients.10 This study was conducted to know the prevalence of candidemia in blood stream and the susceptibility pattern in a tertiary care hospital in North India.

METHODS

This retrospective study was conducted for a period of 1.5 years. Blood cultures received during this period by Becton Dickinson BACTEC 9120 and 9050 automated culture system; were included in the study. Blood sample was collected in automated blood culture bottle under proper aseptic conditions. Then blood culture bottle was put in automated microbial detection system based on the colorimetric detection of carbon dioxide (CO2) produced by microorganisms. After signalling positive for blood culture bottle, samples were inoculated on routine culture media and further tests were performed. The isolates of candida were identified to the species level. Primary identification was done by direct smear examination of blood samples by Gram stain. Sample was inoculated on Sabouraud dextrose agar (SDA) and incubated at 37°C and 25°C for 48 - 72 hours. Typical candida colonies, characterised by smooth, creamy and pasty appearance on SDA were speciated using standard tests such as germ tube test, sugar assimilation test, sugar fermentation test, microscopic morphology on corn meal agar and color production on CHROMagar media (Himedia Laboratories Pvt. Ltd. Mumbai, India).

The candida isolates were also subjected to antifungal susceptibility testing using the disk diffusion method on Müller–Hinton agar with 2 % glucose and 0.5 lg / ml methylene blue, according to the standard Clinical and Laboratory Standards Institute (CLSI) guidelines. Antifungal drugs like amphotericin B (100 units / disc), fluconazole (10 mcg / disc), itraconaole (30 mcg / disc), ketoconazole (10 mcg / disc) and clotrimazole (10 mcg / disc) were used for antifungal susceptibility. For interpretation of sensitivity, zone sizes recommended by the CLSI guidelines corresponding to year were referred to.11 American Type Culture Collection (ATCC) strains C. albicans 90028, Candida parapsilosis 22019 and Candida krusei 6258 were used as controls.

The study protocol was reviewed and approved by the institutional ethics committee and written informed consent was recorded from each of the recruited patients.
Statistical Analysis

Descriptive statistics was used to summarise demographic and other clinical features of patients. Qualitative and quantitative data values were expressed as frequency along with percentage.

RESULTS

During this period of 1.5 years, a total of 8020 blood culture samples were processed out of which total of 80 samples were positive for candida species. Therefore, the overall prevalence rate of isolation of candida species was 0.99 % in our study. Out of the 80 candida isolates, 21 (26.2 %) were Candida albicans, while majority 59 (73.8 %) were NAC species (Figure 1). Among NAC species Candida tropicalis 26 (44 %) was the most common, followed by Candida parapsilosis 14 (24 %), Candida glabrata 10 (17 %), Candida krusei 5 (8.5 %), and Candida guilliermondii 3 (5 %) and Candida dubliniensis 1 (1.5 %) (Figure 2).

Majority of candida species were isolated from adult patients (65 %) followed by patients of age group < 1 year (10 %) whereas 25 % strains were isolated from age group 1 - 18 years. We noted a predominance of male patients (65 %). The male to female ratio was 2:1.

Candidemia was observed in 44 patients from ICU from surgical ICU, medical ICU, paediatric ICU, high dependency unit (HDU) and 36 patients from ward (burn unit ward, haemato-oncology ward, medical ward, paediatric ward and surgical ward). Among ICUs, 25 (56.8 %) patients with candida infection were observed from paediatric ICU followed by 8 (18.1 %), 6 (13.6 %), 5 (11.5 %) from surgical ICU, medical ICU and ward respectively. The candida infection among wards is predominantly seen in haemato-oncology ward followed by paediatric ward, medical ward, surgical ward and burn unit ward with 41.6 %, 8 (22.2 %), 6 (16.6 %), 4 (11.1 %), 3 (8.5 %) patients respectively (Table 2). All these patients who had candidemia have received broad spectrum antibiotics with presence of central venous catheter in 58 (72.6 %) patients and peripheral venous catheter in 17 (21.25 %) patients. There were 53 patients who were on total parenteral nutrition, 26 patients on corticosteroid therapy and 15 patients with diabetes (Table 3).

Antifungal susceptibility profile of Candida species is shown in Table 4. As compared to amphotericin B, Candida albicans demonstrated higher resistance to azole group of antifungal agents. Among azoles, C. albicans, demonstrated good sensitivity against fluconazole (80 %) and ketoconazole (76 %). Azole resistance was significantly higher among NAC species. like Candida tropicalis, Candida glabrata and Candida parapsilosis.

Because Candida krusei is intrinsically resistant to azoles. It was not analysed for sensitivity to the azole group of drugs. Amphotericin B was sensitive in 100 % isolates of
Candida albicans, C. parapsilosis, C. guilliermondii, C. glabrata, C. krusei, followed by Candida tropicalis (96 %). Candida dubliniensis isolate was resistant to amphotericin B. For NAC species, resistance to amphotericin B, fluconazole, ketoconazole, itraconazole and clotrimazole was found in 98 %, 54 %, 61 %, 55 %, and 55 % of the cases, respectively.

For NAC species, resistance to amphotericin B, fluconazole, ketoconazole, itraconazole and clotrimazole was found in 98 %, 54 %, 61 %, 55 %, and 55 % of the cases, respectively.

| Non-albicans Candida Species (39) | Fluconazole | Ketoconazole | Itraconazole | Clotrimazole | Amphotericin B |
|-----------------------------------|-------------|--------------|--------------|--------------|----------------|
| C. tropicalis (26)                | 17 (65 %)   | 20 (76 %)    | 17 (65 %)    | 18 (69 %)    | 25 (96 %)      |
| C. parapsilosis (14)              | 10 (71.4 %) | 12 (85.7 %)  | 8 (57 %)     | 9 (64.2 %)   | 14 (100 %)     |
| C. glabrata (10)                  | 6 (60 %)    | 5 (50 %)     | 4 (40 %)     | 6 (60 %)     | 10 (100 %)     |
| C. krusei (9)                     | 0           | 0            | 0            | 5 (100 %)    |                |
| C. guilliermondii (3)             | 2 (66.6 %)  | 2 (66.6 %)   | 2 (66.6 %)   | 1 (33 %)     | 3 (100 %)      |
| C. dubliniensis (1)               | 1 (100 %)   | 0            | 0            | 1 (100 %)    | 0              |

Table 4. Antifungal Susceptibility Patterns of Non-Candida albicans

**DISCUSSION**

Both albicans and NAC cause invasive candidiasis, and the antifungal resistance of invasive candida aggravates the situation. Increasing number of treatment failures, associated mortality, and shift to more resistant isolates advocate the need for species identification in candida.13 Candidemia is reported as the fourth common cause of BSIs in the intensive care units (ICUs) and account for 10 % of all BSIs. In the present study, candidemia accounted for 0.99 %. There are studies done in India with variable prevalence rate of candidemia which ranges from 0.65 % to 6.9 % (Giri et al. 2013, Verma et al. 2003, Sanhi et al. 2005 and Deorukhkar et al. 2012).14-16 Majority of candida species were isolated from adult male patients followed by patients of age group < 1 year (12 %) whereas 16 % strains were isolated from age group 1 - 15 years. These findings were similar to a number of reports from all around the Indian subcontinent.17,18

In the present study, the predominance of NAC species (73 %) was observed over C. albicans (27 %). It was similar to another study conducted in Haryana, India which had shown 77 % NAC as compared to C. albicans (33 %).21 Recent epidemiological data also revealed a mycological shift from Candida albicans to the nonalbicans candida (NAC) species such as Candida glabrata, Candida tropicalis, Candida parapsilosis, and Candida krusei. It is considered that frequent use of fluconazole as antifungal prophylaxis has played a major role in the emergence of NAC species. Some of these species have been correlated with increased virulence and sometimes with increased mortality.19

More than 90 % of the invasive infections due to candida are attributed to five species; C. albicans, C. glabrata, C. parapsilosis, C. tropicalis and C. krusei. However, the list of new species of candida isolated from clinical specimens continues to grow every year.20 In the present study also, among NAC C. tropicalis was the most common isolate (44 %), Candida parapsilosis (24 %), Candida glabrata (17 %), Candida krusei (8.5 %), Candida guilliermondii (5 %) and Candida dubliniensis (1.5 %). This was similar to other findings done in India.19,21

It was observed in various studies about greater incidence of candidemia in ICUs than wards.22 Also in our country, according to one multicentric study, early colonisation was seen by candida species in Indian ICUs. Lack in healthcare is considered as the important cause of early acquisition of candidaemia post admission in ICU.23 Colonisation in > 70 % neonates has been noticed within a week after delivery in one study in India, the reason of higher incidence of candidemia than developed countries in paediatric ICU is probably due to the higher colonisation.24 Even in our study, the results were similar predominantly paediatric ICU with maximum cases (Table 2).

In a study conducted by Yapur et al. it was found that there are some predisposing factors independently associated with candidemia like catheter, antibiotics usage and total parenteral nutrition.25 According to one Indian study, there is also increased risk of developing candida infection with the increase in usage of broad spectrum antibiotics due to increased duration of stay in hospital.22 Indwelling vascular catheters is considered to be an important risk factor in patients with candidemia. The probable cause of infection is due to strong adherence to materials which is used in intravascular devices.26 In a study done in Uttar Pradesh, India, central venous catheter was seen in 66.7 % of candidemia patients.26 In our study, the similar factors (central venous catheter, antibiotic usage, neutropenia, transfusions and total parenteral nutrition) was seen with 72.6 % candidemia patients with central venous catheter. The results were also similar to one study done by Chow et al. in which central venous catheter was found to be associated with maximum candidemia patients (90 %) as predominant risk factor.27

Many researchers have confirmed that decreased susceptibility to candida is significantly associated with previous antifungal exposure and an inappropriate prior course of antifungal therapy.28,29 In fact, fluconazole exposure was found to be a risk factor for gene mutation and overexposure that leads to future fluconazole-resistant C. parapsilosis.30 It is conceivable that the selective pressure of fluconazole, due to the increased use of this antifungal in some hospitals,31 may be responsible for both the emergence of C. glabrata and fluconazole resistance, with the latter being related to the ability of the microorganism to rapidly develop secondary antifungal resistance due to its haploid state.32 In our study, it was observed that NAC species has significantly high resistance to azoles as compared to C. albicans. These findings are similar to the studies done in northern India and Maharashtra.33,34 It was also observed in our study that C. glabrata has shown highest resistance to azoles. C. glabrata has the highest incidence ofazole resistance among candida clinical isolates and exhibits intrinsic decreased susceptibility to theazole class of antifungals.35

Also, we noticed that among Candida tropicalis isolates fluconazole resistance was 35 %. This is similar to the study results (31 %) from China.36 According to some previous studies indicated that invasive infections caused by C.
*tropicalis* have higher mortality compared to those caused by other non-*tropicalis* candida species.  

Reports of resistance to amphotericin B among isolates of *candida* are limited. However, some species like *C. lusitaniae, C. lipolytica* and *C. guilliermondii* can show intrinsic resistance to amphotericin B. There have been a few reports of strains of *C. albicans* showing resistance to amphotericin B.  

In our study, it has been observed that all *Candida albicans* isolates were sensitive to amphotericin. These findings remained in concordance with a study done by Kaur et al. who quoted that resistance rate was lower for amphotericin B (7.8 %) with candida isolates studied, and Monda et al. reported that all the candida isolates remained sensitive to amphotericin B.  

High resistance to antifungal agents is an alarming sign to the healthcare professionals. Therefore, early and accurate diagnosis of candida infection is essential.

### CONCLUSIONS

With an ever-expanding array of non-candida species-related infections in highly compromised and terminally ill patients, understanding the activity of the antifungal agents used against both *C. albicans* and nonalbicans species becomes mandatory. This study demonstrates significant association of broad spectrum antibiotics and central venous catheters as predominant risk factors for candidemia. It is comforting to know that amphotericin B remains efficacious against both albicans and nonalbicans species. However, fluconazole has exhibited reduced activity, especially among NAC species, and resistance to other azoles has also been encountered among those with acquired resistance to fluconazole. There is a need for continuous surveillance and complete understanding of the important differences among resistance mechanisms employed by these species to combat with this important clinical problem.

Data sharing statement provided by the authors is available with the full text of this article at jebmh.com.

Financial or other competing interests: None.

Disclosure forms provided by the authors are available with the full text of this article at jebmh.com.

### REFERENCES

[1] Afsarian MH, Badali H, Boekhout T, et al. Multilocus sequence typing of *Candida albicans* isolates from a burn intensive care unit in Iran. J Med Microbiol 2015;64(Pt 3):248-253.

[2] Rezaazadeh E, Sabokbar A, Moazenji M, et al. Microdilution in vitro antifungal susceptibility patterns of Candida species, from mild cutaneous to bloodstream infections. Jundishapur J Microbiol 2016;9(7):e34151.

[3] Wisplinhoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39(3):309-317.

[4] Blumberg HM, Jarvis WR, Soucie JM, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: The NEMIS Prospective Multicenter Study. Clin Infect Dis 2001;33(2):177-186.

[5] Stephen BH, Glenn E, Robert F, et al. Risk factors for candidemia: comparison between medical and surgical intensive care unit patients. Chest 2005;128(4):379S-380S.

[6] Pfaffer MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20(1):133-163.

[7] Verma AK, Prasad KN, Singh M, et al. Candidaemia in patients of a tertiary health care hospital from north India. Indian J Med Res 2003;117:122-128.

[8] Kothari A, Sagar V. Epidemiology of candida bloodstream infections in a tertiary care institute in India. Indian J Med Microbiol 2008;27(2):171-172.

[9] Shivaprkashsha S, Radhakrishnan K, Karim PM. Candida spp other than *Candida albicans*: a major cause of fungemia in a tertiary care centre. Indian J Med Microbiol 2007;25(4):405-407.

[10] Trick WE, Fridkin SK, Edwards JR, et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002;35(5):627-630.

[11] Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49(9):3640-3645.

[12] Clinical and Laboratory Standards Institute. Performance standards for antifungal susceptibility testing of yeasts. Supplement M60. 1st edn. Wayne, PA, USA: CLSI 2017.

[13] Sharma Y, Chumber SK, Kaur M. Studying the prevalence, species distribution and detection of in vitro production of phospholipase from *Candida* isolated from cases of invasive candidiasis. J Glob Infect Dis 2017;9(1):8-11.

[14] White TC, Marr KA, Bowden RA. Clinical, cellular and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998;11(2):382-402.

[15] Davis SL, Vazquez JA, McKinnon PS. Epidemiology, risk factors and outcomes of *Candida albicans* versus non- *Candida albicans* candidemia in nonneutropenic patients. Ann Pharmacother 2007;41(4):568-573.

[16] Giri S, Kindo AJ, Kalyani J. Candidemia in intensive care units patients: a one year study from tertiary care hospital, South India. J Postgraduate Med 2013;59(3):190-195.

[17] Sahni V, Agraval SK, Singh NP. Candidemia—an-under recognised nosocomial infection in Indian hospitals. J Associa Physicians India 2005;53:607-611.

[18] Deroukhshkar SC, Saini S. Species distribution and antifungal susceptibility profile of *Candida* species isolated from bloodstream infections. J Evol Med Dent Sci 2012;1(3):241-249.

[19] Deorukhskar SC, Roushani S, Bhalerao D. Candidemia due to non-albicans candida species: risk factors,
species distribution and antifungal susceptibility profile. J Microb Path 2017;1:101.
[20] Pahwa N, Kumar R, Nirkhiwale S, et al. Species distribution and drug susceptibility of candida in clinical isolates from a tertiary care centre at Indore. Indian J Med Microbiol 2014;32(1):44-48.
[21] Sandhu R, Dahiya S, Sayal P, et al. Increased role of nonalbicans Candida, potential risk factors and attributable mortality in hospitalized patients. J Health Res Rev 2017;4(3):78-83.
[22] Tak V, Mathur P, Varghese P, et al. The epidemiological profile of candidiasis at an Indian trauma care center. J Lab Physicians 2014;6(2):96-101.
[23] Chakrabarti A, Sood P, Rudrumurthy SM, et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med 2015;41(2):285-295.
[24] Kaur H, Chakrabarti A. Strategies to reduce mortality in adult and neonatal candidiasis in developing countries. J Fungi (Basel) 2017;3(3):41.
[25] Yapar N, Pullukcu H, Avkan-Oguz V, et al. Evaluation of species distribution and risk factors of candidemia: a multicenter case-control study. Med Mycol 2011;49(1):26-31.
[26] Tejan N, Singla N, Guglani V, et al. Comparison of incidence, risk factors, outcome and antifungal susceptibility between Candida albicans and non-albicans candida species in patients of candidemia in intensive care setting. Int J Pharm Sci Res 2017;8(11):4891-4898.
[27] Chow JK, Golan Y, Ruthazer R, et al. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis 2008;46(8):1206-1213.
[28] Chaudhary U, Goel S, Mittal S. Changing trends of candidemia and antifungal susceptibility pattern in a tertiary health care centre. Infect Disord Drug Targets 2015;15(3):171-176.
[29] Dewan E, Biswas D, Kakati B, et al. Epidemiological and mycological characteristics of candida patients with hematological malignancies attending a tertiary-care center in India. Hematol Oncol Stem Cell Ther 2015;8(3):99-105.
[30] Lortholary O, Desnos-Ollivier M, Sitbon K, et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidiasis: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 2011;55(2):532-538.
[31] Shah DN, Yau R, Lasco TM, et al. Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-non-susceptible Candida species in hospitalized patients with candidemia. Antimicrob Agents Chemother 2012;56(6):3239-3243.
[32] Souza ACR, Fuchs BB, Pinhati HMS, et al. Candida parapsilosis resistance to fluconazole: molecular mechanisms and in vivo impact in infected galleria mellonella larvae. Antimicrob Agents Chemother 2015;59(10):6581-6587.
[33] Abi-Said D, Anaissie E, Uzun O, et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997;24(6):1122-8.
[34] Fidel PL Jr, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis and clinical disease with comparison to C. albicans. Clin Microbiol Rev 1999;12(1):80-96.
[35] Oxman DA, Chow JK, Frendl G, et al. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern? J Antimicrob Chemother 2010;65(7):1460-1465.
[36] Castanheira M, Messer SA, Rhomberg PR, et al. Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013). Diagn Microbiol Infect Dis 2016;85(2):200-204.
[37] Andes DR, Safdar N, Baddley JW, et al. The epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: results of the Transplant-Associated Infection Surveillance Network (TRANSPORT). Transpl Infect Dis 2016;18(6):921-931.
[38] Nolte FS, Parkinson T, Falconer DJ, et al. Isolation and characterisation of fluconazole and amphotericin B resistant Candida albicans from blood of two patients with leukaemia. Antimicrob Agents Chemother 1997;41(1):196-199.
[39] Kaur R, Dhakad MS, Goyal R, et al. Emergence of non-albicans Candida species and antifungal resistance in intensive care unit patients. Asian Pac J Trop Biomed 2016;6(5):455-460.
[40] Mondal S, Mondal A, Pal N, et al. Species distribution and in vitro antifungal susceptibility patterns of Candida. J Inst Med 2013;35(1):45-49.